Beyond their glucose-lowering effects, SGLT-2 inhibitors have been demonstrated to benefit the cardiovascular system in numerous clinical studies, making them a promising therapy for patients with HFrEF, with or without diabetes, and thus, have been recommended as the first-line treatment for HFrEF in several clinical guidelines [32, 33]. Here, SLC5A2 is linked to diabetes mellitus.